ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0294

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs: Results Through 5 Years from the SELECT-BEYOND Study
Abstract Number: 0295

Safety and Efficacy of Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs: Results Through 5 Years from the SELECT-NEXT Study
Abstract Number: 1939

Safety and Humoral Response Following the Second and Third Doses of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents with Juvenile-onset Autoimmune Inflammatory Rheumatic Diseases
Abstract Number: 0715

Safety and Immunogenicity of Mixed COVID19 Vaccine Regimens in Immune-mediated Inflammatory Diseases: An Observational Cohort
Abstract Number: 1061

Safety and Tolerability of Aminaphtone in Systemic Sclerosis Patients: A Four-year Follow-up
Abstract Number: 1077

Safety of Avacopan in ANCA-Associated Vasculitis: Combined Data from Three Clinical Trials
Abstract Number: 2132

Safety of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor: As Assessed by Laboratory Parameters – Results from a Phase 2 Trial in Psoriatic Arthritis and 2 Phase 3 Trials in Psoriasis
Abstract Number: 0280

Safety of Filgotinib in Patients with RA: Laboratory Analysis Results from a Long-Term Extension Study
Abstract Number: 2120

Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of 11 Phase 2/3 Clinical Studies in Psoriasis and Psoriatic Arthritis
Abstract Number: 1085

Safety of Plasmapheresis as an Adjuvant Therapy in Severe Pediatric Anti-neutrophil Cytoplasmic Antibody Associated Vasculitis: A Single Center Cohort
Abstract Number: 1765

Safety of the Recombinant Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis Treated with JAKi Drugs
Abstract Number: 1635

Safety Profile of Hydroxychloroquine in a Large Cohort of Rheumatology Patients Within the US Department of Defense Military Healthcare System
Abstract Number: 0988

Safety, Pharmacokinetics, and Pharmacodynamics of Single Oral Enpatoran Doses in a Phase I Study of Healthy Japanese and Caucasian Participants: Feasibility of Including Asian Participants in a Phase II Study of Enpatoran
Abstract Number: 2244

Salient Coping Strategies Among Youth with Chronic Musculoskeletal Pain
Abstract Number: 2023

Salivary Autoantibodies in Sicca Patients Are Associated with Dry Symptoms

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].